Dose Escalation Approved and Dosing Commenced in Second Cohort of GPN Vaccines’ Phase 1 Clinical Trial
Adelaide, Australia, 30th March 2023 – GPN Vaccines Ltd is pleased to announce that dose escalation has been approved and dosing of the second cohort has commenced in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial is assessing...
March 30, 2023